Skip to main content
. 2024 Jan 29;14(3):287. doi: 10.3390/diagnostics14030287

Figure 4.

Figure 4

Molecular activity prediction analysis of breast carcinoma, development of breast carcinoma, and metastasis of breast carcinoma in HER2− molecular subtype. The figure shows the downregulation of TP53 and PTEN secondary to loss of function mutations predicts the development of breast carcinoma. The downregulation of AKT1 was enough to predict inhibited breast carcinoma metastasis. CP = canonical pathway. Rx = drug being tested in clinical trials.